Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man
Open accessThe DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 10 of the 73 sources its claims cite were checked for support.
Abstract
We hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration, and prevent hypoglycemia when glucagon secretion is deficient. Accordingly, we assessed the impact of glucagon deficiency, produced by infusion of somatostatin with insulin, without and with pharmacologic alpha- and beta-adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects. During somatostatin with insulin alone mean glucose production fell from 1.5 +/- 0.05 to 0.7 +/- 0.2 mg/kg per min and mean plasma glucose declined from 93 +/- 3 to 67 +/- 4 mg/dl over 1 h; glucose production then increased to base-line rates and plasma glucose plateaued at 64-67 mg/dl over 2 h. This plateau was associated with, and is best attributed to, an eightfold increase in mean plasma epinephrine. It did not occur when adrenergic blockade was added; glucose production remained low and mean plasma glucose declined progressively to a hypoglycemic level of 45 +/- 4 mg/dl, significantly (P less than 0.001) lower than the final value during somatostatin with insulin alone. These data provide further support for the concept that maintenance of the postabsorptive plasma glucose concentration is a function of insulin and glucagon, not of insulin alone, and that adrenergic mechanisms do not normally play a critical role. They indicate, however, that an endogenous adrenergic agonist, likely adrenomedullary epinephrine, compensates for deficient glucagon secretion and prevents hypoglycemia in the postabsorptive state in humans. Thus, postabsorptive hypoglycemia occurs when both glucagon and epinephrine are deficient, but not when either glucagon or epinephrine alone is deficient, and insulin is present.
Overview
CoChat Summary
TL;DR
In normal humans, glucagon deficiency produced by somatostatin plus insulin caused an initial fall in glucose production and plasma glucose, followed by a rebound in glucose production and a glucose plateau at 64–67 mg/dl. Adding α- and β-adrenergic blockade prevented the plateau and led to progressive hypoglycemia (45±4 mg/dl), indicating that epinephrine compensates for deficient glucagon secretion to support postabsorptive glucose and prevent hypoglycemia.
Key findings
- During somatostatin with insulin alone, mean glucose production fell from 1.5±0.05 to 0.7±0.2 mg/kg per min at 50 min, and mean plasma glucose declined from 93±3 to 67±4 mg/dl at 60 min, then plateaued at 64–67 mg/dl; the 180-min value was 64±4 mg/dl, not significantly different from 60 min.
- With added propranolol plus phentolamine, the initial glucose fall was similar, but plasma glucose declined progressively to 45±4 mg/dl at 180 min, significantly lower than 64±4 mg/dl during somatostatin with insulin alone (P < 0.001); glucose production remained below baseline and was significantly lower by 80 min (P < 0.05), with no changes in glucose utilization.
- Plasma epinephrine rose more than eightfold, from 18±4 to 153±33 pg/ml at 180 min (P < 0.01), during somatostatin with insulin alone; norepinephrine rose from 156±11 to 271±29 pg/ml (P < 0.01).
- Blood lactate rose from 770±84 to 1,095±136 μmol/liter at 130 min (P < 0.02) during somatostatin with insulin alone, and this rise did not occur with adrenergic blockade; blood glycerol also fell progressively with blockade, supporting biologically active epinephrine release.
Methods
- 10 normal human subjects (six women, four men), ages 18–33 yr and within 15% of ideal body weight, were studied after an overnight fast in the supine position.
- A primed continuous [3-3H]glucose infusion was used; somatostatin (250 μg/h) plus regular porcine insulin (200 μU/kg per min) was infused from 0 through 180 min, with or without propranolol (0.08 mg/min after 5.0 mg over 2 min) and phentolamine (0.5 mg/min after 5.0 mg over 2 min) from −30 through 180 min; study sequence was randomized.
- Plasma glucose, glucose kinetics, insulin, C-peptide, glucagon, growth hormone, cortisol, epinephrine, norepinephrine, and blood alanine, lactate, glycerol, and β-hydroxybutyrate were measured; data are mean±SE and were analyzed with a paired t test.
Limitations
- The paper states that the insulin dose was a compromise: it could not produce isolated glucagon deficiency with portal insulin at baseline levels, and the protocol produced mild peripheral venous hyperinsulinemia (~20–60% above baseline) with estimated portal venous insulin approximately two-thirds of baseline.
- The paper notes that measured glucagon decrements were small because the antiserum cross-reacts with species other than 3,500-dalton glucagon, although biologically active glucagon was likely suppressed substantially; it also states that the data do not exclude an additional effect of epinephrine on glucose utilization during glucagon deficiency.
- Evident from the text: the study is small (10 normal subjects), acute (3 h), uses pharmacologic nonselective adrenergic blockade, and does not directly measure portal insulin or glucagon concentrations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 16 Not checked · 38 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since the normal hepatic portal-to-peripheral venous insulin concentration ratio is ~2.5:1.0 (29–32), this mild peripheral hyper-nsn n s s sn ns linemia.”
What the sources say
- Not checked — no full text of the sourcecites [29] 29. Felig, P., R. Gusberg, R. Hendler, F. E. Gump, and J. M. Kinney. 1974. Concentrations of glucagon and the insulin:glucagon ratio in the portal and peripheral circulation. Proc. Soc. Exp. Biol. Med. 147:8890. source
- Not checked — no full text of the sourcecites [30] 30. Dencker, H., P. Hedner, J. Holst, and H.-G. Tranberg. 1975. Pancreatic glucagon response to an ordinary meal. Scand. J. Gastroenterol. 10:471–474. source
- Not checked — no full text of the sourcecites [31] 31. Walter, R. M., Jr., E. M. Gold, C. A. Michas, and J. W. Ensinck. 1980. Portal and peripheral vein concentrations of insulin and glucagon after arginine infusion in morbidly obese subjects. Metab. Clin. Exp. 29:1037-1040. source
- Supportedcites [32] 32. Horwitz, D. L., J. I. Starr, M. E. Mako, W. G. Blackard, and A. H. Rubenstein. 1975. Proinsulin, insulin and C-peptide concentrations in human portal and peripheral blood. J. Clin. Invest. 55:1278–1283. source
Table I reports basal portal insulin of 0.97 ng/ml and peripheral insulin of 0.36 ng/ml, a ratio of about 2.7:1, consistent with the cited approximate 2.5:1 ratio. The citation is attached to that normal ratio; the subsequent inference about somatostatin and portal hypoinsulinemia is not a finding tested in this paper. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, the principles of hypoglycemic glucose counterregulation (1-7) and those of nonhypoglycemic glucose counterregulation in both the postprandial (8, 9) and the postabsorptive states are fundamentally the same.”
What the sources say
- Partly supportedcites [1] 1. Garber, A. J., P. E. Cryer, J. V. Santiago, M. W. Haymond, A. S. Pagliara, and D. M. Kipnis. 1976. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J. Clin. Invest. 58:7–15. sourceExperimental — accuracy not yet measured
Our copy of Garber et al. (1976) supports only the hypoglycemic half of the attributed point: the Abstract (p. 1) and Discussion (pp. 6) conclude that adrenergic mechanisms probably initiate the counter-regulatory responses to insulin-induced hypoglycemia in normal volunteers, with catecholamine increments preceding or coinciding with the rise in glucose production. The paper never states that these principles are 'fundamentally the same' as those of nonhypoglycemic counterregulation, and it does not examine postprandial or postabsorptive regulation at all (searches for postabsorptive/postprandial/physiologic counterregulation returned only the hypoglycemia protocol, Introduction p. 1). On the contrary, the Discussion (p. 6) closes by withholding exactly that extension: 'a role for adrenergic mechanisms in the modulation of more physiologic fluctuations in the plasma glucose concentration remains to be established.' The equivalence claim across hypoglycemic and nonhypoglycemic (postprandial, postabsorptive) counterregulation is therefore the citing authors' generalization, not this source's finding. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [2] 2. Clarke, W. L., J. V. Santiago, L. Thomas, M. W. Haymond, E. Ben-Galim, and P. E. Cryer. 1979. Adrenergic mechanisms in recovery from hypoglycemia in man: adrenergic blockade. Am. J. Physiol. 236:E147-E152. source
- Not checked — no full text of the sourcecites [3] 3. Gerich, J., J. Davis, M. Lorenzi, R. Rizza, N. Bohannon, J. Karam, S. Lewis, S. Kaplan, T. Schultz, and P. E. Cryer. 1979. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am. J. Physiol. 236:E380-E385. source
- Not checked — no full text of the sourcecites [4] 4. Rizza, R. A., P. E. Cryer, and J. E. Gerich. 1979. Role of glucagon, epinephrine and growth hormone in human glucose counter-regulation: effects of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin-induced hypoglycemia. J. Clin. Invest. 64:62–71. source
- Not checked — no full text of the sourcecites [5] 5. Cryer, P. E. 1981. Glucose counterregulation in man. Diabetes. 30:261-264. source
- Partly supportedcites [6] 6. Popp, D. A., S. D. Shah, and P. E. Cryer. 1982. The role of epinephrine mediated β-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin dependent diabetes mellitus. J. Clin. Invest. 69:315-326. sourceExperimental — accuracy not yet measured
Our copy of Popp, Shah and Cryer (1982) squarely supports the hypoglycemic limb of the claim: the INTRODUCTION states that 'glucagon secretion is normally the primary determinant of glucose recovery from hypoglycemia and that enhanced epinephrine secretion largely compensates for deficient glucagon secretion,' and the Discussion ('Posthypoglycemic hyperglycemia in patients with IDDM') closes by saying the findings 'provide further support for our model (1-4) of the mechanisms of hypoglycemic glucose counterregulation.' However, the paper nowhere asserts that these principles are 'fundamentally the same' as those of nonhypoglycemic counterregulation, and it contains no postprandial or postabsorptive data — nonhypoglycemic plasma glucose decrements appear only in the INTRODUCTION as a cited observation of blunted glucagon responses in IDDM, credited to another work (reference 8, Santiago, Clarke, Shah and Cryer 1980). The equivalence across hypoglycemic and nonhypoglycemic, postprandial and postabsorptive states is therefore the citing authors' synthesis, not something this source states. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [7] 7. White, N. H., D. Skor, P. E. Cryer, D. M. Bier, L. Levandowski, and J. V. Santiago. 1983. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N. Engl. J. Med. 308:485–491. source
- Partly supportedcites [8] 8. Tse, T. F., W. E. Clutter, S. D. Shah, J. P. Miller, and P. E. Cryer. 1983. Neuroendocrine responses to glucose ingestion in man: specificity, temporal relationships and quantitative aspects. J. Clin. Invest. 72:270– 277. sourceExperimental — accuracy not yet measured
The Introduction and Discussion support a role for counterregulatory factors after glucose ingestion, the postprandial setting addressed by this paper. But the Introduction says that the extent to which findings about hypoglycemic counterregulation can be extrapolated to nonhypoglycemic counterregulation is unknown. The paper therefore does not establish that the principles are fundamentally the same, and it does not study the postabsorptive state (section labels supplied without page numbers). (LLM, conf=0.86)
- Supportedcites [9] 9. Tse, T. F., W. E. Clutter, S. D. Shah, and P. E. Cryer. 1983. The mechanisms of postprandial glucose counterregulation in man: physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J. Clin. Invest. 72:278286. source
The citation is attached to postprandial counterregulation. In the Discussion (p. 8), the paper describes striking parallels between hypoglycemic counterregulation and the nonhypoglycemic counterregulation it studied late after glucose ingestion, including the roles of glucagon and epinephrine. The sentence does not attach this citation specifically to the postabsorptive state. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and postabsorptive plasma glucose concentrations are not discernibly reduced in epinephrine-deficient (adrenalectomized) persons (3, 9).”
What the sources say
- Not checked — no full text of the sourcecites [3] 3. Gerich, J., J. Davis, M. Lorenzi, R. Rizza, N. Bohannon, J. Karam, S. Lewis, S. Kaplan, T. Schultz, and P. E. Cryer. 1979. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am. J. Physiol. 236:E380-E385. source
- Partly supportedcites [9] 9. Tse, T. F., W. E. Clutter, S. D. Shah, and P. E. Cryer. 1983. The mechanisms of postprandial glucose counterregulation in man: physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J. Clin. Invest. 72:278286. sourceExperimental — accuracy not yet measured
The Results (p. 5) report that mean plasma glucose levels in epinephrine-deficient, bilaterally adrenalectomized patients were not significantly different from those in normal subjects. But that comparison was made late after glucose ingestion, not in the postabsorptive state specified in the claim. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More recently it has been shown that the same principles apply to nonhypoglycemic glucose counterregulation”
What the sources say
- Partly supportedcites [8] 8. Tse, T. F., W. E. Clutter, S. D. Shah, J. P. Miller, and P. E. Cryer. 1983. Neuroendocrine responses to glucose ingestion in man: specificity, temporal relationships and quantitative aspects. J. Clin. Invest. 72:270– 277. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says that glucagon is primary and epinephrine compensates when glucagon is deficient in hypoglycemic counterregulation, but explicitly says it is unknown whether those findings extend to nonhypoglycemic counterregulation. The Discussion (page unavailable) finds hormone changes consistent with a counterregulatory role after glucose ingestion; it does not establish that the same principles apply. (LLM, conf=0.87)
- Supportedcites [9] 9. Tse, T. F., W. E. Clutter, S. D. Shah, and P. E. Cryer. 1983. The mechanisms of postprandial glucose counterregulation in man: physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J. Clin. Invest. 72:278286. source
The Discussion (p. 8) explicitly draws parallels between hypoglycemic and nonhypoglycemic glucose counterregulation. It says glucagon has a primary role in both, epinephrine compensates for deficient glucagon in both, and counterregulation fails only when both are absent. The authors limit this comparison to the rapid counterregulation models they studied. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Plasma C-peptide, insulin, and glucagon concentrations were comparable under both study conditions.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
31 more claims
Create a free account to see all 60 claims and to verify the 13 references still open.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 10
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These findings provide further support for the concept, based upon physiological and clinical evidence (1–6), that glucose counterregulatory systems are involved in the prevention, as well as the correction, of hypoglycemia in humans.”
From Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. (1987) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 2
“There were no changes in glucose utilization (plasma glucose disappearance rate, Ra).”
§ Results · p. 2
“Somatostatin with insulin resulted in an initial fall in glucose production (plasma glucose appearance rate, Ra) from 1.5±0.05 mg/kg per min to a nadir of 0.7±0.2 mg/kg per min at 50 min (Fig. 1).”
Citations
Cites
Immunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
Effect of Ischemia on Known Substrates and Cofactors of the Glycolytic Pathway in Brain
Lowry, O. H., Passonneau, J. V., Hasselberger, F. X., & Schulz, D. W. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51740-3 · Cited by 2,221
Cryer, P. E., Haymond, M. W., Santiago, J. V., & Shah, S. D. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609092951101 · Cited by 1,101
Self-citationHormone-fuel interrelationships during fasting.
Cahill, G. F., Herrera, M. G., Morgan, A. P., Soeldner, J. S., Steinke, J., Levy, P. L., Reichard, G. A., & Kipnis, D. M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105481 · Cited by 1,036
A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma
SCHALCH, D. S., & PARKER, M. L. (1964) · Nature · doi:10.1038/2031141a0 · Cited by 635
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., Blix, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
Clutter, W. E., Bier, D. M., Shah, S. D., & Cryer, P. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109840 · Cited by 576
Self-citationON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE.
DeBodo, R. C., Steele, R., ALTSZULER, N., Dunn, A., & Bishop, J. (1963) · PubMed · Cited by 532
Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.
Horwitz, D. L., Starr, J. I., Mako, M. E., Blackard, W. G., & Rubenstein, A. H. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108047 · Cited by 473
Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation
Rizza, R. A., Cryer, P. E., & Gerich, J. E. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109464 · Cited by 421
Self-citation
Cited by
Service, F. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321707 · Cited by 503
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112884 · Cited by 394
Self-citationGlucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus
Epstein, F. H., Cryer, P. E., & Gerich, J. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130405 · Cited by 273
Self-citationMinireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Self-citationGlucose counterregulation: prevention and correction of hypoglycemia in humans
Cryer, P. E. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.2.e149 · Cited by 198
Self-citation
Metadata
- Authors
- Rosen, S. G., Clutter, W. E., Berk, M. A., Shah, S. D., & Cryer, P. E.
- Affiliations
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1984-02-01
- Volume
- 73
- Issue
- 2
- Pages
- 405-411
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC425031
- OpenAlex
- W1984337511
- Cited by
- 41
- References
- 44
- Citations by year
- 2024: 1 · 2020: 1 · 2016: 1
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- epinephrine, glucagon deficiency, hypoglycemia, adrenergic mechanisms, glucose kinetics, glucose production, somatostatin, insulin, alpha-adrenergic blockade, beta-adrenergic blockade
- MeSH terms
- Absorption, Adolescent, Adult, Blood Glucose, Epinephrine, Female, Glucagon, Humans, Insulin, Kinetics, Male, Norepinephrine, Phentolamine, Propranolol, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. https://app.cochat.ai/papers/10.1172/jci111226
- The paper
- Rosen, S. G., Clutter, W. E., Berk, M. A., Shah, S. D., & Cryer, P. E. (1984). Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. Journal of Clinical Investigation. https://doi.org/10.1172/jci111226
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.